20/20 BioLabs Charts Path Toward Medicare Reimbursement for OneTest™ MCED Blood Test, Reports Strong Q2 Revenue Growth
核心洞察
20/20 BioLabs (搜索) outlined its strategy to position OneTest™ for Cancer (搜索) for potential Medicare reimbursement under a new statutory pathway for FDA-authorized MCED blood tests beginning in 2028.
The company's approach uses protein tumor markers, inflammation-associated biomarkers, machine learning, and serial testing rather than circulating tumor DNA-based methods, potentially enabling earlier detection.
More than 35,000 American firefighters are expected to be tested by end of 2026, providing real-world data to support the company's regulatory and reimbursement strategy.
20/20 BioLabs (搜索), Inc. (Nasdaq: AIDX) detailed its strategy for advancing OneTest™ for Cancer (搜索) toward potential Medicare reimbursement during its inaugural investor webinar held on July 1, 2026. The Gaithersburg, Maryland-based company is positioning its AI-powered, multi-cancer early detection (MCED) blood test to capitalize on recently enacted federal legislation that creates a Medicare coverage pathway for FDA-authorized MCED tests beginning in 2028.
The company emphasized that Medicare reimbursement for OneTest™ would require both FDA authorization and a CMS determination of clinical appropriateness — milestones that have not yet been achieved. "While substantial regulatory and reimbursement work remains, we believe this approach offers a differentiated path toward making multi-cancer early detection more accessible to Medicare beneficiaries and other large populations," said Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs (搜索).
A Differentiated Approach: Protein Biomarkers and Serial Tracking
Unlike competing MCED tests that rely on circulating tumor DNA (ctDNA) analysis, OneTest™ employs a panel of protein tumor markers and inflammation-associated biomarkers combined with machine learning algorithms. The company's platform emphasizes serial testing to monitor biomarker trajectories over time rather than relying on a single diagnostic snapshot.
The webinar reviewed concerns raised by experts regarding the clinical utility profile of certain ctDNA-only approaches for broad population screening, including recent randomized trial data from a large U.K. study. 20/20 BioLabs (搜索) believes its longitudinal approach may support earlier detection, improved specificity through trend analysis, and more practical repeat testing using at-home capillary blood collection via upper-arm devices.
Evidence-Generation Strategy and Real-World Data
The company outlined a comprehensive evidence-generation strategy encompassing real-world screening data, international clinical datasets, published "look-alike" protein tumor marker panel studies, potential validation using banked U.S. biospecimens, and outcomes from high-risk populations.
A cornerstone of this strategy involves American firefighters, with more than 35,000 expected to have been tested by the end of 2026. The company anticipates this population will provide important real-world data to support its regulatory and reimbursement objectives.
Revenue Momentum
20/20 BioLabs (搜索) also disclosed preliminary financial estimates indicating that its second quarter MCED revenue is expected to be the highest to date, at least 30% higher than the prior-year second quarter (three months ended June 30, 2025). These estimates are based on preliminary numbers that have not yet been reviewed by the company's auditors.
OneTest™ for Longevity (搜索) Platform
Beyond cancer detection, the company highlighted its OneTest™ for Longevity (搜索) platform, which integrates inflammatory biomarkers, dietary assessment tools, and personalized health insights. The company discussed how repeat testing and dietary-inflammatory scoring may complement its broader prevention-focused strategy, including potential alignment with federal initiatives focused on nutrition, chronic disease prevention, and health optimization.
M&A Strategy and Forward Outlook
The presentation also addressed the company's mergers and acquisitions strategy, targeting companies with overlapping customer bases in health, wellness, early cancer detection, longevity testing, and nutrition-related markets.
The company cautioned that the investor webinar presentation included modeled sensitivity and specificity estimates and revenue projections that are hypothetical illustrations based on stated assumptions. These estimates are not measured trial results and are not guarantees of future clinical or financial performance.
OneTest™ for Cancer (搜索) has not received FDA De Novo authorization or premarket approval and is currently offered as a laboratory-developed test in the company's CLIA-licensed and CAP-accredited laboratory.